Nifty
Sensex
:
:
23501.10
77209.90
-65.90 (-0.28%)
-269.03 (-0.35%)

Pharmaceuticals & Drugs - Global

Rating :
55/99

BSE: 532523 | NSE: BIOCON

345.70
21-Jun-2024
  • Open
  • High
  • Low
  • Previous Close
  •  345.50
  •  351.00
  •  340.10
  •  342.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  9300900
  •  32229.15
  •  351.00
  •  217.50

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 41,492.74
  • 40.58
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 54,963.64
  • 0.14%
  • 2.10

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 60.64%
  • 1.46%
  • 15.53%
  • FII
  • DII
  • Others
  • 5.63%
  • 13.58%
  • 3.16%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.53
  • 15.17
  • 16.09

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.92
  • 13.53
  • 10.23

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 1.12
  • -12.54
  • -17.36

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 59.08
  • 62.47
  • 62.67

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.95
  • 4.59
  • 3.53

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.46
  • 20.16
  • 16.83

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Sep 23
Sep 22
Var%
Jun 23
Jun 22
Var%
Net Sales
3,917.10
3,773.90
3.79%
3,953.70
2,941.10
34.43%
3,462.30
2,319.70
49.26%
3,422.60
2,139.50
59.97%
Expenses
3,001.20
2,776.60
8.09%
3,026.90
2,296.80
31.79%
2,720.70
1,849.00
47.14%
2,708.20
1,740.10
55.63%
EBITDA
915.90
997.30
-8.16%
926.80
644.30
43.85%
741.60
470.70
57.55%
714.40
399.40
78.87%
EBIDTM
23.38%
26.43%
23.44%
21.91%
21.42%
20.29%
20.87%
18.67%
Other Income
48.60
154.90
-68.62%
565.50
78.60
619.47%
157.90
64.50
144.81%
93.50
77.90
20.03%
Interest
227.00
248.80
-8.76%
266.70
120.30
121.70%
247.70
30.00
725.67%
233.00
19.90
1,070.85%
Depreciation
407.00
363.70
11.91%
414.50
301.10
37.66%
389.30
230.80
68.67%
358.00
217.50
64.60%
PBT
321.70
536.70
-40.06%
832.30
30.10
2,665.12%
238.50
257.40
-7.34%
216.90
239.90
-9.59%
Tax
96.10
82.10
17.05%
54.90
-4.80
-
41.60
147.30
-71.76%
34.80
29.50
17.97%
PAT
225.60
454.60
-50.37%
777.40
34.90
2,127.51%
196.90
110.10
78.84%
182.10
210.40
-13.45%
PATM
5.76%
12.05%
19.66%
1.19%
5.69%
4.75%
5.32%
9.83%
EPS
1.13
2.61
-56.70%
5.50
-0.35
-
1.05
0.39
169.23%
0.84
1.20
-30.00%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Net Sales
14,755.70
11,174.20
8,184.00
7,143.10
6,300.50
5,514.40
4,123.40
3,891.10
3,347.40
3,089.80
2,877.30
Net Sales Growth
32.05%
36.54%
14.57%
13.37%
14.26%
33.73%
5.97%
16.24%
8.34%
7.39%
 
Cost Of Goods Sold
4,897.90
3,663.10
2,718.40
2,243.70
1,989.50
1,896.60
1,636.10
1,446.60
1,290.40
1,255.60
1,186.10
Gross Profit
9,857.80
7,511.10
5,465.60
4,899.40
4,311.00
3,617.80
2,487.30
2,444.50
2,057.00
1,834.20
1,691.20
GP Margin
66.81%
67.22%
66.78%
68.59%
68.42%
65.61%
60.32%
62.82%
61.45%
59.36%
58.78%
Total Expenditure
11,457.00
9,054.70
6,691.40
5,841.00
5,043.50
4,390.60
3,294.30
2,911.60
2,584.30
2,394.00
2,190.20
Power & Fuel Cost
-
414.80
316.40
270.30
246.10
239.80
189.00
156.40
184.70
176.70
162.40
% Of Sales
-
3.71%
3.87%
3.78%
3.91%
4.35%
4.58%
4.02%
5.52%
5.72%
5.64%
Employee Cost
-
2,181.00
1,880.10
1,741.00
1,458.80
1,165.30
931.10
747.00
610.10
533.40
466.30
% Of Sales
-
19.52%
22.97%
24.37%
23.15%
21.13%
22.58%
19.20%
18.23%
17.26%
16.21%
Manufacturing Exp.
-
1,917.20
1,243.50
1,019.20
864.60
721.20
335.70
391.50
203.70
81.20
62.90
% Of Sales
-
17.16%
15.19%
14.27%
13.72%
13.08%
8.14%
10.06%
6.09%
2.63%
2.19%
General & Admin Exp.
-
359.60
181.50
270.50
182.10
53.00
56.80
21.70
144.60
165.70
131.80
% Of Sales
-
3.22%
2.22%
3.79%
2.89%
0.96%
1.38%
0.56%
4.32%
5.36%
4.58%
Selling & Distn. Exp.
-
221.60
243.80
235.90
266.30
277.50
98.20
107.40
100.80
108.70
118.90
% Of Sales
-
1.98%
2.98%
3.30%
4.23%
5.03%
2.38%
2.76%
3.01%
3.52%
4.13%
Miscellaneous Exp.
-
297.40
107.70
60.40
36.10
37.20
47.40
41.00
50.00
72.70
118.90
% Of Sales
-
2.66%
1.32%
0.85%
0.57%
0.67%
1.15%
1.05%
1.49%
2.35%
2.15%
EBITDA
3,298.70
2,119.50
1,492.60
1,302.10
1,257.00
1,123.80
829.10
979.50
763.10
695.80
687.10
EBITDA Margin
22.36%
18.97%
18.24%
18.23%
19.95%
20.38%
20.11%
25.17%
22.80%
22.52%
23.88%
Other Income
865.50
768.10
690.30
605.20
507.50
414.30
206.20
157.10
83.90
53.10
55.90
Interest
974.40
419.00
67.60
57.70
64.90
70.90
61.50
26.00
29.30
8.90
1.70
Depreciation
1,568.80
1,113.10
814.20
715.10
552.20
447.80
385.10
277.20
248.70
221.00
203.60
PBT
1,609.40
1,355.50
1,301.10
1,134.50
1,147.40
1,019.40
588.70
833.40
569.00
519.00
537.70
Tax
227.40
254.10
211.50
221.50
315.10
212.30
156.90
161.60
142.20
95.70
106.90
Tax Rate
14.13%
23.88%
17.77%
19.31%
25.94%
17.49%
26.65%
19.39%
19.49%
15.33%
19.88%
PAT
1,382.00
462.70
648.40
819.90
777.10
904.40
351.10
595.80
528.70
497.40
413.80
PAT before Minority Interest
1,106.70
643.00
771.60
925.60
899.80
1,001.70
431.80
671.80
587.40
528.40
430.80
Minority Interest
-275.30
-180.30
-123.20
-105.70
-122.70
-97.30
-80.70
-76.00
-58.70
-31.00
-17.00
PAT Margin
9.37%
4.14%
7.92%
11.48%
12.33%
16.40%
8.51%
15.31%
15.79%
16.10%
14.38%
PAT Growth
70.62%
-28.64%
-20.92%
5.51%
-14.08%
157.59%
-41.07%
12.69%
6.29%
20.20%
 
EPS
11.51
3.85
5.40
6.83
6.47
7.53
2.92
4.96
4.40
4.14
3.45

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Shareholder's Funds
17,866.90
8,432.50
7,626.90
6,705.80
6,098.00
5,180.80
4,837.70
4,033.80
3,270.60
3,026.70
Share Capital
600.30
600.30
600.00
600.00
300.00
300.00
100.00
100.00
100.00
100.00
Total Reserves
16,992.60
7,628.10
6,872.80
5,997.00
5,720.80
4,812.30
4,670.20
3,873.00
3,132.70
2,806.20
Non-Current Liabilities
20,742.30
6,802.70
5,496.90
2,684.70
2,122.30
2,006.50
2,304.60
2,421.30
1,377.90
1,262.00
Secured Loans
13,692.30
2,574.30
1,492.40
1,220.80
1,523.50
1,787.00
2,104.30
2,061.00
758.20
580.40
Unsecured Loans
1,598.20
1,424.20
1,469.20
1.40
2.10
2.80
3.90
11.40
11.40
25.80
Long Term Provisions
226.50
91.70
106.20
85.80
66.10
49.30
36.00
29.90
15.00
7.80
Current Liabilities
8,510.70
3,828.00
4,210.10
4,008.00
3,038.50
2,141.30
1,678.30
1,665.70
1,554.70
1,379.60
Trade Payables
3,983.10
1,608.50
1,513.90
1,325.10
1,198.30
1,005.30
739.70
609.80
429.30
347.20
Other Current Liabilities
1,673.80
1,031.20
1,840.20
1,784.40
1,374.70
870.10
698.20
527.10
706.20
612.30
Short Term Borrowings
2,480.20
896.00
594.20
667.60
261.20
130.30
97.20
394.90
261.00
243.50
Short Term Provisions
373.60
292.30
261.80
230.90
204.30
135.60
143.20
133.90
158.20
176.60
Total Liabilities
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60
Net Block
29,467.70
6,569.00
6,363.90
5,971.10
4,471.00
3,699.50
3,625.10
1,748.30
1,629.90
1,525.20
Gross Block
35,321.40
11,233.00
10,220.90
9,147.40
7,095.00
5,873.80
5,436.10
3,403.60
3,034.20
2,701.70
Accumulated Depreciation
5,853.70
4,664.00
3,857.00
3,176.30
2,624.00
2,174.30
1,811.00
1,655.30
1,404.30
1,176.50
Non Current Assets
39,407.80
11,718.40
10,614.20
8,750.80
6,979.20
5,647.70
5,149.00
4,415.70
3,812.80
3,111.80
Capital Work in Progress
7,317.00
4,110.40
2,800.20
2,196.00
1,898.90
1,302.80
839.20
2,239.50
1,676.40
1,205.60
Non Current Investment
742.30
370.20
743.20
108.50
182.50
63.80
188.80
26.80
0.00
64.50
Long Term Loans & Adv.
683.20
483.80
436.40
402.00
335.80
437.20
319.70
350.10
336.90
252.00
Other Non Current Assets
1,197.60
185.00
270.50
73.20
91.00
144.40
176.20
51.00
169.60
64.50
Current Assets
12,334.00
8,382.30
7,600.40
5,325.00
4,888.50
4,148.60
4,047.70
3,970.90
2,562.60
2,638.80
Current Investments
1,326.50
1,217.70
1,208.70
857.60
829.30
611.40
1,065.00
874.70
230.30
700.40
Inventories
4,243.70
2,298.20
1,866.60
1,435.90
1,031.60
722.50
635.30
542.40
452.70
376.60
Sundry Debtors
3,573.20
2,058.20
1,503.30
1,223.70
1,291.80
1,063.90
883.20
714.50
770.50
599.80
Cash & Bank
2,400.10
1,747.50
2,015.40
998.60
1,057.20
1,322.80
1,044.30
1,538.60
937.50
804.40
Other Current Assets
790.50
660.20
713.10
543.60
678.60
428.00
419.90
300.70
171.60
157.60
Short Term Loans & Adv.
456.40
400.50
293.30
265.60
153.10
54.70
24.10
134.70
75.80
81.80
Net Current Assets
3,823.30
4,554.30
3,390.30
1,317.00
1,850.00
2,007.30
2,369.40
2,305.20
1,007.90
1,259.20
Total Assets
51,741.80
20,100.70
18,214.60
14,075.80
11,867.70
9,796.30
9,196.70
8,386.60
6,375.40
5,750.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Cash From Operating Activity
1,852.50
1,176.60
1,159.70
1,283.10
1,154.60
662.10
640.00
370.60
210.70
560.70
PBT
897.10
983.10
1,067.70
870.90
1,002.60
610.00
849.70
751.30
624.10
537.70
Adjustment
1,685.00
1,245.00
709.60
921.40
472.60
355.70
204.40
42.00
74.00
134.00
Changes in Working Capital
-501.00
-789.50
-423.80
-165.10
-29.10
-106.50
-211.10
-176.20
-354.00
37.70
Cash after chg. in Working capital
2,081.10
1,438.60
1,353.50
1,627.20
1,446.10
859.20
843.00
617.10
344.10
709.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-228.60
-262.00
-193.80
-344.10
-291.50
-197.10
-203.00
-246.50
-133.40
-148.70
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-14,281.80
-1,699.10
-3,624.70
-1,558.90
-713.80
-684.00
-498.50
-1,141.70
-508.70
-938.10
Net Fixed Assets
-260.40
-284.70
-130.90
744.40
-280.60
-177.90
-215.90
-216.90
-57.90
-322.80
Net Investments
-3,990.70
202.20
-456.90
-890.30
107.80
-310.70
-79.30
-3,688.10
328.50
125.80
Others
-10,030.70
-1,616.60
-3,036.90
-1,413.00
-541.00
-195.40
-203.30
2,763.30
-779.30
-741.10
Cash from Financing Activity
13,048.70
242.10
2,564.00
387.60
-241.70
-239.70
-177.50
1,067.60
186.20
426.00
Net Cash Inflow / Outflow
619.40
-280.40
99.00
111.80
199.10
-261.60
-36.00
296.50
-111.80
48.60
Opening Cash & Equivalents
653.70
897.00
824.70
659.30
449.00
710.20
757.50
457.50
557.00
474.00
Closing Cash & Equivalent
1,294.80
653.70
897.00
824.70
659.30
449.00
710.20
757.50
462.60
557.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Book Value (Rs.)
146.53
68.53
62.27
54.97
50.17
42.59
39.74
33.10
26.93
24.21
ROA
1.79%
4.03%
5.73%
6.94%
9.25%
4.55%
7.64%
7.96%
8.72%
8.47%
ROE
4.98%
9.83%
13.16%
14.26%
18.00%
8.74%
15.37%
16.31%
17.22%
15.68%
ROCE
5.37%
8.30%
11.30%
14.35%
16.11%
8.92%
12.59%
13.93%
15.30%
15.75%
Fixed Asset Turnover
0.48
0.77
0.74
0.78
0.85
0.73
0.89
1.05
1.09
1.12
Receivable days
91.14
79.19
69.67
72.86
77.96
86.05
74.35
80.16
80.09
69.48
Inventory Days
105.87
92.60
84.38
71.47
58.05
60.00
54.81
53.71
48.47
48.54
Payable days
278.58
209.62
230.92
81.60
81.98
87.98
78.68
71.28
58.15
55.73
Cash Conversion Cycle
-81.57
-37.84
-76.87
62.74
54.04
58.07
50.48
62.59
70.42
62.29
Total Debt/Equity
1.01
0.60
0.58
0.40
0.40
0.44
0.48
0.62
0.35
0.30
Interest Cover
3.14
15.54
20.88
19.72
18.12
10.57
33.05
25.90
71.12
317.29

News Update:


  • Biocon gets nod for Micafungin from USFDA
    4th Jun 2024, 09:28 AM

    The approval further strengthens Biocon’s portfolio of vertically integrated, complex drug products

    Read More
  • Biocon signs exclusive licensing, supply agreement with Handok
    24th May 2024, 09:22 AM

    Handok is amongst Korea’s leading companies in the management of diabetes, offering a host of solutions from diagnosis to treatment and care

    Read More
  • Biocon’s arm gets USFDA’s nod for Yesafili
    21st May 2024, 09:30 AM

    The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States

    Read More
  • Biocon reports 46% fall in Q4 consolidated net profit
    17th May 2024, 11:43 AM

    Total consolidated income of the company increased by 0.94% at Rs 3965.70 crore for Q4FY24

    Read More
  • Biocon - Quarterly Results
    16th May 2024, 17:16 PM

    Read More
  • Biocon signs exclusive distribution, supply agreement with Medix
    13th May 2024, 09:25 AM

    The company has signed agreement for the commercialization of its vertically integrated drug product, Liraglutide

    Read More
  • Biocon signs licensing and supply agreement with Biomm S.A.
    18th Apr 2024, 09:17 AM

    Biomm is Brazil’s first and only biotechnology focused company, providing high quality healthcare to patients with chronic conditions and enhancing access to the latest technologies and treatments

    Read More
  • Biocon’s arm transfers branded formulations business in India to Eris Lifesciences
    3rd Apr 2024, 11:17 AM

    The transaction is completed on April 2, 2024

    Read More
  • Biocon gets approval from MHRA, UK for complex formulation Liraglutide
    28th Mar 2024, 09:39 AM

    Liraglutide is a drug-device combination formulation used in the treatment of Type 2 Diabetes Mellitus

    Read More
  • Biocon’s arm enters into long-term commercial collaboration with Eris Lifesciences
    15th Mar 2024, 14:09 PM

    As a part of this collaboration, Biocon Biologics will continue to leverage Eris’ strong commercial footprint to significantly expand patient access to its world class biosimilars in India

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.